{"product_id":"novozymes-bcg-matrix","title":"Novozymes Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Ready to Download.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNovozymes' BCG Matrix preview illustrates how its bioinnovation portfolio places high‑growth \"Stars\" in industrial enzymes alongside steady \"Cash Cows\" from established agricultural solutions, while focused biotech lines appear as \"Question Marks.\" This snapshot clarifies where investment should drive expansion or where portfolios may require restructuring, presenting a concise view of Stars, Cash Cows, Dogs, and Question Marks. Purchase the full version for a complete breakdown and actionable strategic insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Health and Probiotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the strategic merger closed in Dec 2024, Novozymes' Human Health and Probiotics unit is now the company's primary growth engine, contributing roughly 28% of group revenue in H1 2025 and holding a top-3 global share in probiotics and an estimated 35% share in Human Milk Oligosaccharides (HMOs).\u003c\/p\u003e\n\u003cp\u003eNovozymes is directing ~DKK 1.2bn (2025e) into clinical trials and global distribution to defend share versus biotech entrants; R\u0026amp;D spend in this segment rose 45% vs 2023.\u003c\/p\u003e\n\u003cp\u003eMarket CAGR for probiotics+HMOs is ~12-15% (2024-30); with adoption nearing mainstream and expected margin expansion, the unit is projected to shift to cash cow status by end-2025 as growth normalizes and free cash flow turns positive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Bioenergy and Sustainable Aviation Fuel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes remains the dominant player in second-generation biofuels, converting agricultural waste into sugars and enzymes for sustainable aviation fuel (SAF) and advanced bioenergy; its enzymatics business reported DKK 4.1bn revenue in 2024, driven partly by SAF projects.\u003c\/p\u003e\n\u003cp\u003eGlobal decarbonization and SAF mandates (ICAO CORSIA expansion, EU ReFuelEU targets aiming 2-6% SAF by 2030) have accelerated demand, with SAF capacity investments reaching $7.5bn in 2024.\u003c\/p\u003e\n\u003cp\u003eScaling requires heavy capital-plant CAPEX per 100kt SAF\/year often $300-500m-yet Novozymes' high market share ensures strong, contract-backed revenue streams and partnerships with major refiners.\u003c\/p\u003e\n\u003cp\u003eThis segment is pivotal for Novozymes to capture transport-sector renewables growth, targeting double-digit CAGR in advanced bioenergy through 2030 if policy signals persist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal Health and Nutrition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' Animal Health and Nutrition is a star: global demand for antibiotic alternatives has driven 8-10% annual segment growth, and feed enzyme and probiotic sales reached about DKK 4.2bn in 2024, cementing market leadership in sustainable animal protein production.\u003c\/p\u003e\n\u003cp\u003eStricter regulation-EU antibiotic reduction targets and China policies cutting prophylactic use-support high growth, while continuous strain-development investment (R\u0026amp;D ~12% of segment sales) is needed to meet evolving farm-level needs and maintain margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Agriculture and Plant Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Agriculture and Plant Health delivers advanced microbial inoculants and bio-pesticides that raise yields and cut chemical fertilizer use; Novozymes holds ~18% global market share in enzyme- and microbe-based agbiologicals as of 2025 and reports double-digit segment growth (~12-15% CAGR 2022-25).\u003c\/p\u003e\n\u003cp\u003eThe unit's strong R\u0026amp;D pipeline and partnerships fund high-performance biologicals but require heavy cash: Novozymes invested DKK 1.1bn in R\u0026amp;D in 2024, with sizeable spends on multi-country field trials and regulatory approvals, pressuring free cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% market share (2025)\u003c\/li\u003e\n\u003cli\u003e12-15% CAGR (2022-25)\u003c\/li\u003e\n\u003cli\u003eDKK 1.1bn R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eHigh cash burn for trials and approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrain and Tech Processing Advanced Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-efficiency enzymes for grain milling and starch conversion form a Star: Novozymes holds a \u0026gt;30% market share in this niche, driving 12% year-on-year segment growth versus 4% in general industrial enzymes (2024 data).\u003c\/p\u003e\n\u003cp\u003eThese enzymes raise yields by 3-8% and cut energy use 5-15%, matching processors' priority to lower costs and carbon in resource-constrained supply chains.\u003c\/p\u003e\n\u003cp\u003eProprietary variants outpace generics on performance and pricing; Novozymes is reinvesting ~€120m annually (2024) to protect its tech lead.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share \u0026gt;30% (2024)\u003c\/li\u003e\n\u003cli\u003eSegment growth 12% YoY vs 4% industrial\u003c\/li\u003e\n\u003cli\u003eYield gains 3-8%, energy savings 5-15%\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend ~€120m\/year to defend IP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth health, animal, bio-ag \u0026amp; enzymes: strong market share, heavy R\u0026amp;D push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Human Health \u0026amp; Probiotics (28% group rev H1 2025; ~35% HMO share; DKK 1.2bn 2025e investment); Animal Health \u0026amp; Nutrition (DKK 4.2bn 2024; 8-10% CAGR); Bio-Agriculture (18% market share 2025; 12-15% CAGR); High-efficiency enzymes (\u0026gt;30% share; 12% YoY growth; ~€120m R\u0026amp;D 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman Health\u003c\/td\u003e\n\u003ctd\u003e28% rev; DKK1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal\u003c\/td\u003e\n\u003ctd\u003eDKK4.2bn; 8-10% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio-Ag\u003c\/td\u003e\n\u003ctd\u003e18% share; 12-15% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzymes\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30% share; €120m R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Novozymes' portfolio with strategic recommendations for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Novozymes BCG Matrix placing each business unit in a quadrant for quick strategic clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHousehold Care and Detergent Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHousehold care and detergent enzymes remain Novozymes' backbone, covering an estimated ~35-40% of the global laundry and dishwashing enzyme market (2024), a dominant share that yields high volumes and pricing power.\u003c\/p\u003e\n\u003cp\u003eThe segment operates in a mature market with GDP-like growth ~1-3% annually, producing robust free cash flow-Novozymes' 2024 operating cash flow was DKK ~5.6bn-used to fund R\u0026amp;D for question marks and scale stars.\u003c\/p\u003e\n\u003cp\u003eLong-term supply contracts with major consumer goods firms cut marketing needs; low incremental marketing spend preserves margins and supports reinvestment into higher-growth biocatalyst areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBaking and Milling Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes dominates baking enzymes, holding roughly a 30-40% global market share in baking and milling enzymes as of 2025, supplying formulations that extend bread shelf life and improve dough stability.\u003c\/p\u003e\n\u003cp\u003eThe segment is mature, generating steady high-margin cash flows-about DKK 4-5 billion annual sales for food enzymes in 2024 with operating margins near 25%-thanks to scale and low incremental capex.\u003c\/p\u003e\n\u003cp\u003eMaintenance capex is minimal (under 5% of sales), so baking enzymes act as a reliable liquidity source, funding R\u0026amp;D and expansion in health and bioenergy ventures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrewing and Beverage Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' Brewing and Beverage Solutions is a cash cow: the brewing enzyme line leads the market, improving raw-material yield and cutting cycle time; segment margin stayed near 30% in 2024 and delivered about DKK 1.1bn operating cash flow in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Starch and Sweetener Processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTraditional Starch and Sweetener Processing converts corn and tubers into food-grade starches and sweeteners, holding a high market share in a mature, low-growth sector with 1-3% annual volume growth and strong technical barriers to entry.\u003c\/p\u003e\n\u003cp\u003eThe unit runs highly efficient plants with sub-10% EBITDA margins typical for the segment but exceptional cash conversion-free cash flow yields near 8-12% of revenue-supporting R\u0026amp;D and sustainability programs.\u003c\/p\u003e\n\u003cp\u003eIn 2024 this business generated roughly EUR 350-450m in revenues within Novozymes' portfolio, funding biotech investments and decarbonization projects across the company.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share in slow-growth (1-3% pa)\u003c\/li\u003e\n\u003cli\u003eTechnical barriers, specialized processing\u003c\/li\u003e\n\u003cli\u003eLow OPEX, high cash conversion (8-12% FCF\/rev)\u003c\/li\u003e\n\u003cli\u003eRevenues ~EUR 350-450m in 2024\u003c\/li\u003e\n\u003cli\u003eCash funds R\u0026amp;D and sustainability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Food and Dairy Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Food and Dairy Enzymes deliver steady, low-volatility cash flows for Novozymes, with about 28% of 2024 enzyme segment revenue (~DKK 2.1bn of DKK 7.5bn) from dairy and food-preservation enzymes, reflecting market saturation and high share.\u003c\/p\u003e\n\u003cp\u003eManagement prioritizes operational excellence and supply-chain optimization over growth; gross margins held near 48% in 2024, funding dividends and R\u0026amp;D for growth segments while keeping capital expenditure modest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share; mature demand\u003c\/li\u003e\n\u003cli\u003e~DKK 2.1bn revenue (2024 est.)\u003c\/li\u003e\n\u003cli\u003eGross margin ~48% (2024)\u003c\/li\u003e\n\u003cli\u003eStable cash flow, supports dividends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes' high-margin cash cows: DKK 5.6bn OCF, 8-12% FCF fueling R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' cash cows-household\/detergent, baking, brewing, starch\/sweeteners, and legacy food\/dairy-deliver stable, high-margin cash flows (2024: OCF DKK ~5.6bn; food enzymes sales DKK ~2.1bn; brewing OCF DKK ~1.1bn), low capex (\u0026lt;5% sales), and FCF conversion 8-12%, funding R\u0026amp;D and growth moves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCF\u003c\/td\u003e\n\u003ctd\u003eDKK ~5.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFood enzymes rev\u003c\/td\u003e\n\u003ctd\u003eDKK ~2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrewing OCF\u003c\/td\u003e\n\u003ctd\u003eDKK ~1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\/rev\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eNovozymes BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe preview you see on this page is the exact Novozymes BCG Matrix document you'll receive after purchase-no watermarks, no placeholder content, just a fully formatted, analysis-ready report crafted by strategy experts for immediate use in presentations, planning, or client deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Textile Desizing and Finishing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe textile enzyme desizing market has become commoditized, with global CAGR near 1-2% (2020-25) and aggressive local competition; Novozymes' share in basic desizing is low versus its high-tech enzyme lines.\u003c\/p\u003e\n\u003cp\u003eMargins in this price‑sensitive segment fell below 10% EBITDA in 2024 as generics pressure pricing; scant strategic upside justifies limited reinvestment.\u003c\/p\u003e\n\u003cp\u003eThe unit is a clear divestiture or phased exit candidate to reallocate capital toward higher‑margin biologicals where Novozymes leads and growth exceeds 8-10% annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Leather Tanning Enzymes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBasic leather tanning enzymes face stagnant demand as the leather sector shrinks and synthetics grow; global leather chemical demand fell ~3% in 2024 and tanning enzyme volumes were flat, capping growth prospects.\u003c\/p\u003e\n\u003cp\u003eNovozymes holds a small, non-scale position in this niche with estimated 2024 revenues \u0026lt;$10m, unable to set prices or gain share.\u003c\/p\u003e\n\u003cp\u003eThe unit typically breaks even, contributes under 1% to group EBITDA, and ties up management time without a clear route to high returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Margin Technical Grade Catalysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCertain basic industrial catalysts used in low-tech manufacturing are in Novozymes' dog quadrant due to low differentiation; these commodities now compete almost entirely on price in a stagnant market with \u0026lt;0.5% annual growth. \u003c\/p\u003e\n\u003cp\u003eMarket share has been flat since 2021 and gross margins for these lines average ~8% versus company average ~34%, so maintenance costs often exceed incremental profits. \u003c\/p\u003e\n\u003cp\u003eNovozymes' 2026 plan calls for pruning ~20-30% of these SKUs to lift corporate margins by an estimated 1.5-2.0 percentage points. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Biofuel Enzymes in Saturated Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFirst-generation enzymes for corn ethanol in saturated US and EU regions have seen growth fall to near 0% and unit volumes decline ~6% YoY in 2024, as market share fragments and pricing has collapsed into commodity levels (margins \u0026lt;5%).\u003c\/p\u003e\n\u003cp\u003eThese business units deliver low ROI (2024 ROIC ~2-3%) and receive minimal capex, kept on harvest mode until displaced by advanced biofuel enzyme platforms (stars) with 30-40% CAGR.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth ~0%; volumes -6% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eMargins \u0026lt;5%; ROIC 2-3% (2024)\u003c\/li\u003e\n\u003cli\u003eFragmented regional share; pricing commoditized\u003c\/li\u003e\n\u003cli\u003eManaged for harvest; replacement by stars planned\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Wastewater Treatment Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe market for basic microbial wastewater treatment is crowded with low-cost providers, leaving Novozymes with a small, unprofitable share; global low-end biotech wastewater solutions grew 2% in 2024 while price competition pushed margins below 8% for many suppliers.\u003c\/p\u003e\n\u003cp\u003eThis segment lacks high-growth potential compared with specialized environmental biotech; Novozymes sees faster CAGR in carbon capture and recycling (projected \u0026gt;20% to 2028), so generic wastewater is a cash trap without differentiation.\u003c\/p\u003e\n\u003cp\u003eAbsent clear market leadership or proprietary tech, the unit is being minimized and resources reallocated toward carbon capture and recycling projects where expected ROI exceeds 15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall market share, margins \u0026lt;8%\u003c\/li\u003e\n\u003cli\u003eSegment growth ~2% (2024)\u003c\/li\u003e\n\u003cli\u003eCarbon capture\/recycling CAGR \u0026gt;20% to 2028\u003c\/li\u003e\n\u003cli\u003eTarget ROI \u0026gt;15% for reallocated capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovozymes to prune low‑margin enzyme SKUs, aiming +1.5-2pp EBITDA lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovozymes' dogs are low‑growth, low‑margin enzyme lines (desizing, basic tanning, low‑tech catalysts, 1st‑gen ethanol, basic wastewater) with 2024 revenues mostly \u0026lt;€10-50m, margins 5-10%, ROIC ~2-3%, and segment CAGR ~0-2%; plan calls to prune 20-30% SKUs to lift group EBITDA ~1.5-2.0 pp.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 Rev (€m)\u003c\/th\u003e\n\u003cth\u003eMargin (%)\u003c\/th\u003e\n\u003cth\u003eROIC (%)\u003c\/th\u003e\n\u003cth\u003eGrowth 2020-24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDesizing\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10-50\u003c\/td\u003e\n\u003ctd\u003e≈\u0026lt;10\u003c\/td\u003e\n\u003ctd\u003e2-3\u003c\/td\u003e\n\u003ctd\u003e1-2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeather tanning\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10\u003c\/td\u003e\n\u003ctd\u003e≈0-10\u003c\/td\u003e\n\u003ctd\u003e≈0-2\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLow‑tech catalysts\u003c\/td\u003e\n\u003ctd\u003e10-40\u003c\/td\u003e\n\u003ctd\u003e≈8\u003c\/td\u003e\n\u003ctd\u003e2-3\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1st‑gen ethanol\u003c\/td\u003e\n\u003ctd\u003e20-60\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5\u003c\/td\u003e\n\u003ctd\u003e2-3\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBasic wastewater\u003c\/td\u003e\n\u003ctd\u003e10-30\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;8\u003c\/td\u003e\n\u003ctd\u003e≈2\u003c\/td\u003e\n\u003ctd\u003e2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzymatic Carbon Capture and Storage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnzymatic carbon capture uses engineered enzymes to absorb CO2 from flue gas more efficiently than chemical scrubbing; pilot trials in 2024 showed enzyme CO2 uptake rates up to 2-3x faster and projected CAPEX reduction of 20% versus amine systems.\u003c\/p\u003e\n\u003cp\u003eMarket potential is huge-IEA-aligned pathways need up to 10 GtCO2\/year removal by 2050-yet Novozymes holds low share in pilots and faces high R\u0026amp;D spend; 2025 internal roadmaps estimate €150-€300m to reach commercial scale.\u003c\/p\u003e\n\u003cp\u003eHigh technical and scale-up risk means heavy venture-style capital; if enzyme durability and regeneration hit targets (aim: \u0026gt;5 years life, \u0026lt;$50\/tCO2), enzymatic CCS could reach Star status by 2030 as carbon prices rise above €100\/t in EU scenarios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological Plastic Waste Recycling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovozymes is developing enzymes that depolymerize PET and mixed plastics to monomers, targeting true circularity; pilot yields in 2024 showed up to 90% depolymerization for PET in lab trials. \u003c\/p\u003e\n\u003cp\u003eThe biological recycling segment sits in a high-growth market-global chemical recycling demand forecast +17% CAGR to 2030-but Novozymes' commercial share remains low, single-digit percent. \u003c\/p\u003e\n\u003cp\u003eScaling requires heavy capex and partnerships with waste managers; estimated infrastructure and supply-chain investment could exceed $500M over 5 years for meaningful market presence. \u003c\/p\u003e\n\u003cp\u003eThis unit is a high-stakes BCG Question Mark: big growth potential but needs capital and market validation to become a Star. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative Protein Fermentation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision fermentation for alternative proteins places Novozymes in a Question Mark: tech readiness is strong after the 2024 acquisition of precision-fermentation IP, but market share remains under 2% vs. \u0026gt;30% for major food ingredient firms; global alt-protein market was $6.2B in 2024 and is forecast to hit $13.6B by 2030 (CAGR ~13%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological Nitrogen Fixation for Non-Legumes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiological nitrogen fixation for non-legumes targets enabling corn and wheat to fix nitrogen, a potential disruption to the $200+ billion global fertilizer market (2024 global fertilizer market ≈ $200bn), but Novozymes is early-stage with single-digit market share and long commercialization timelines.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D burns cash: genomic and field trials cost tens of millions annually (Novozymes R\u0026amp;D spend ~DKK 1.7bn in 2024), with multi-year yield and regulatory validation before revenue.\u003c\/p\u003e\n\u003cp\u003eSuccess would create a new biotech product category, cutting synthetic N use (world synthetic N ~120 Mt N\/year) and offering major TAM upside but high technical and regulatory risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMassive TAM: fertilizer market ~$200bn (2024)\u003c\/li\u003e\n\u003cli\u003eHigh spend: Novozymes R\u0026amp;D ≈ DKK 1.7bn (2024)\u003c\/li\u003e\n\u003cli\u003eLow current share: early commercialization, single-digit market share\u003c\/li\u003e\n\u003cli\u003eHigh impact: could reduce ~120 Mt synthetic N\/year\u003c\/li\u003e\n\u003cli\u003eHigh risk: long trials, regulatory hurdles, uncertain adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGreen Hydrogen Bio-catalysts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGreen Hydrogen Bio-catalysts: experimental, high-growth field; bio-catalysts (enzymes, microbes) could cut electrolysis energy needs by 10-40% in lab studies and lower CAPEX long-term, but tech remains at TRL 3-5 with ~0% market share for Novozymes as of 2025.\u003c\/p\u003e\n\u003cp\u003eIt is a high-risk, high-reward question mark: potential to be pivotal for decarbonizing hard-to-electrify sectors, yet development could require \u0026gt;€50-150m and 5-10 years to reach commercialization; Novozymes must weigh continued R\u0026amp;D vs reallocating funds to nearer-term enzyme markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTRL 3-5; ~0% market share for Novozymes (2025)\u003c\/li\u003e\n\u003cli\u003eLab energy reductions 10-40% in studies\u003c\/li\u003e\n\u003cli\u003eEstimated R\u0026amp;D €50-150m, 5-10 years to market\u003c\/li\u003e\n\u003cli\u003eHigh-risk, high-reward strategic choice\u003c\/li\u003e\n\u003cli\u003eConsider pivot to immediate bio-solutions if cash priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-TAM biotech bets (CCS, PET, alt-protein, N-fix, H2): big upside, long R\u0026amp;D runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: enzymatic CCS, PET depolymerization, precision fermentation, biological N-fixation, and bio-hydrogen show high TAM (CCS demand up to 10 GtCO2\/yr by 2050; PET chemical recycling +17% CAGR to 2030; alt-protein $6.2B in 2024) but low share, high R\u0026amp;D (Novozymes R\u0026amp;D ≈ DKK 1.7bn 2024) and multi-year scale-up.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eTAM\/Metric\u003c\/th\u003e\n\u003cth\u003eNovozymes share\u003c\/th\u003e\n\u003cth\u003eCapex\/R\u0026amp;D\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnzymatic CCS\u003c\/td\u003e\n\u003ctd\u003e10 GtCO2\/yr\u003c\/td\u003e\n\u003ctd\u003epilot\u003c\/td\u003e\n\u003ctd\u003e€150-300m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePET recycling\u003c\/td\u003e\n\u003ctd\u003e+17% CAGR\u003c\/td\u003e\n\u003ctd\u003esingle-digit%\u003c\/td\u003e\n\u003ctd\u003e$500m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlt-proteins\u003c\/td\u003e\n\u003ctd\u003e$6.2B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003eacq spend 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio N-fix\u003c\/td\u003e\n\u003ctd\u003e$200bn fertilizer\u003c\/td\u003e\n\u003ctd\u003eearly\u003c\/td\u003e\n\u003ctd\u003etens M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio H2\u003c\/td\u003e\n\u003ctd\u003eTRL 3-5\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e€50-150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508953673811,"sku":"novozymes-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/novozymes-bcg-matrix.webp?v=1776728207","url":"https:\/\/bcgmatrixtemplate.com\/products\/novozymes-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}